Clinical Trial: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Platinum-resistant Ovarian Cancer
Study Type: INTERVENTIONAL
Official Title: An Open-Label, Phase 1b Study of SL-172154 (SIRP?-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian Cancers
Brief Summary:
SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer.Approximately 102 patients will be enrolled in this study in two phases: dose escalation and dose expansion.
Read more